The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls

Kahal, Hassan; Kilpatrick, E; Rigby, Alan S.; Coady, AM; Atkin, Stephen L.

doi:10.1080/09513590.2018.1505848

Cited by 26 publications

(24 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, the antidepressant effects of GLP-1R agonists were proved 27,47 . A meta-analysis indicated that GLP-1 analogs resulted in a significant reduction of depression rating scales 28 .…”

Section: Discussionmentioning

confidence: 99%

PET evaluation of light-induced modulation of microglial activation and GLP-1R expression in depressive rats

et al. 2021

View full text Add to dashboard Cite

Light therapy has been accepted as a promising therapeutic choice for depression. Positron emission tomography (PET) combined with specific radiotracers has great benefits for revealing pathogenesis and developing therapeutics. This study aimed to investigate the influences of light therapy on microglial activation and glucagon-like peptide-1 receptor (GLP-1R) expression in the brain of depressive rats using [18F]DPA-714 and [18F]exendin-4 PET. The results showed that chronic unpredictable mild stress (CUMS)-induced depressive rats had poorer performance in behavioral tests compared to normal rats (p < 0.05) and the depressive-like behavior could be ameliorated by light therapy. Besides, depressive rats had significantly higher [18F]DPA-714 uptake and lower [18F]FDG uptake compare to normal rats in 11 and 9 regions of interest (ROIs) of the brain, respectively (p < 0.05). After 5 weeks of light therapy, higher [18F]FDG and [18F]exendin-4 uptake was observed in most ROIs of light therapy-treated depressive rats compared to untreated depressive rats (p < 0.05) and no significant differences existed in [18F]DPA-714 uptake between the two groups. This study demonstrated that light therapy can ameliorate depressive-like behavior, improve glucose metabolism, and halt the decline of brain GLP-1R expression of depressive rats, but have no effects on microglial activation caused by CUMS. Besides, this study validated that [18F]DPA-714 and [18F]exendin-4 PET have the potential for noninvasive evaluation of microglial activation and GLP-1R expression in the brain of depression.

show abstract

Section: Discussionmentioning

confidence: 99%

PET evaluation of light-induced modulation of microglial activation and GLP-1R expression in depressive rats

et al. 2021

View full text Add to dashboard Cite

show abstract

“…There was also a significant improvement in the social health, physical and psychological components of the World Health Organization QOL questionnaire (WHOQOL-BREF). 53…”

Section: Evidence For the Therapeutic Potentials Of Glp-1 Ra In Pcosmentioning

confidence: 99%

The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence

Abdalla

Deshmukh

Atkin

et al. 2021

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Introduction: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects women of reproductive age. Metabolic consequences associated with PCOS include, but are not limited to, insulin resistance (IR), type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). This narrative review aims to provide a comprehensive overview of the potential therapeutic roles of the incretin-based therapies in the management of PCOS. Methods: We performed a systematic search of databases including PubMed, MEDLINE and EMBASE up to 1 October 2020. We developed a search string of medical subject headings (MeSH) including the terms PCOS, incretin mimetics, glucagon-like peptide-1 (GLP-1), glucagon-like peptide-1 receptor antagonists (GLP-1 RAs), liraglutide, exenatide, semaglutide, dipeptidyl peptidase-4 (DPP-4) inhibitors, combined with IR, testosterone and sex hormone-binding globulin (SHBG). Results: We identified 854 relevant articles and, after the initial screening, eight interventional animal studies, one observational animal study, 14 interventional human studies, two case–control studies and one systematic review were included. These studies showed the potential significant roles of GLP-1 RAs and DPP-4 inhibitors in the management of PCOS, with significant improvements in the metabolic parameters, including substantial weight reduction and improved insulin sensitivity. These agents also improved the hormonal parameters through decreased free androgen and increased SHBG. Moreover, they improved menstrual regularity, increased fertility with enhanced ovulation and pregnancy in obese women with PCOS. Conclusion: GLP-1 RAs and DPP-4 inhibitors have a promising therapeutic role in PCOS; however, larger clinical trials are needed to establish the role of incretin-based therapies in the management of PCOS.

show abstract

“… 71 Another trial that examined the effect of liraglutide (1.8 mg) on quality of life (QOL) and depression in obese PCOS patients showed a dramatic weight reduction which significantly improved QOL. 72 …”

Section: Treatment Options For Managing Metabolic Comorbiditiesmentioning

confidence: 99%

A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome

Abdalla

Deshmukh

Atkin

et al. 2020

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age. Metabolic sequelae associated with PCOS range from insulin resistance to type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Insulin resistance plays a significant role in the pathophysiology of PCOS and it is a reliable marker for cardiometabolic risk. Although insulin sensitising agents such as metformin have been traditionally used for managing metabolic aspects of PCOS, their efficacy is low in terms of weight reduction and cardiovascular risk reduction compared with newer agents such as incretin mimetics and SGLT2 inhibitors. With current pharmaceutical advances, potential therapeutic options have increased, giving patients and clinicians more choices. Incretin mimetics are a promising therapy with a unique metabolic target that could be used widely in the management of PCOS. Likewise, bariatric procedures have become less invasive and result in effective weight loss and the reversal of metabolic morbidities in some patients. Therefore, surgical treatment targeting weight loss becomes increasingly common in the management of obese women with PCOS. Newer emerging therapies, including twincretins, triple GLP-1 agonists, glucagon receptor antagonists and imeglemin, are promising therapeutic options for treating T2DM. Given the similarity of metabolic and pathological features between PCOS and T2DM and the variety of therapeutic options, there is the potential to widen our strategy for treating metabolic disorders in PCOS in parallel with current therapeutic advances. The review was conducted in line with the recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018.

show abstract

The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls

Cited by 26 publications

References 23 publications

PET evaluation of light-induced modulation of microglial activation and GLP-1R expression in depressive rats

PET evaluation of light-induced modulation of microglial activation and GLP-1R expression in depressive rats

The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence

A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome

Contact Info

Product

Resources

About